KPV (Lysine-Proline-Valine) 250mcg/60caps

Full-length alpha-MSH activates the canonical melanocortin receptors (primarily MC1R), a G protein-coupled receptor pathway producing cAMP-dependent downstream signalling.

KPV, as a minimal C-terminal tripeptide fragment, is investigated for effects in cell-based models (including NF-κB transcriptional readouts) that appear to occur with reduced dependence on classical MC1R-mediated signalling, making it a research tool for distinguishing melanocortin receptor-dependent from receptor-independent peptide activity.

Researchers studying this distinction typically use MC1R antagonists or receptor-knockout/knockdown models alongside KPV exposure to determine the receptor-dependence of observed effects.

Standard approaches include NF-κB-responsive luciferase reporter assays in cell lines stimulated with a pro-inflammatory trigger (such as LPS or TNF-α) with and without KPV co-treatment, alongside direct measurement of NF-κB nuclear translocation by immunofluorescence or Western blot of nuclear/cytoplasmic fractions. Downstream readouts often include quantification of NF-κB target gene products (pro-inflammatory cytokines, chemokines) by ELISA or qPCR to characterise the functional consequence of any observed transcriptional modulation.

Because the Lys-Pro-Val sequence is conserved in both alpha-MSH and ACTH at the same relative position, KPV serves as a minimal structural probe for research questions about which biological activities of these larger peptide hormones map to this specific C-terminal motif versus other regions of the parent sequence. Comparative studies using KPV alongside other fragments of alpha-MSH/ACTH (such as the N-terminal or central regions) allow researchers to build structure-activity maps of the full hormone sequence.